Plus Therapeutics Inc Stock Price, News & Analysis

Plus Therapeutics (PSTV) announced the initiation of the ReSPECT-LM Phase 1/2a clinical trial for Rhenium-186 NanoLiposome (186RNL), targeting leptomeningeal metastases (LM). The first patient has been dosed in this multicenter study, which evaluates safety, tolerability, and maximum tolerated/dose feasible doses of 186RNL. This treatment aims to address the unmet medical need for LM patients, who face poor survival rates and lack FDA-approved options. The FDA has granted Fast Track designation for 186RNL, allowing for expedited development and review.

Plus Therapeutics (Nasdaq: PSTV) is set to sponsor and present an industry satellite symposium titled Radiolabeled NanoLiposomes: A Novel Targeted Treatment for Rare and Central Nervous System Cancers at the Society of Nuclear Medicine and Molecular Imaging Therapeutics Conference from March 10-12, 2022, in New Orleans. The presentation will take place on March 12 at 7:15 a.m. CT, led by Chief Medical Officer Norman LaFrance. Plus Therapeutics focuses on developing radiotherapeutics, including its lead candidate, Rhenium-186 NanoLiposome, targeting recurrent glioblastoma.

Plus Therapeutics (PSTV) reported financial results for Q4 and full year 2021, showing a net loss of $13.4 million, or $(1.11) per share, compared to $8.2 million, or $(1.86) per share, in 2020. The company raised $28.5 million to strengthen its balance sheet, with cash balances at $23 million as of January 31, 2022. Notable advancements include positive interim data from the ReSPECT-GBM Phase 1/2 trial of 186RNL, plans for a Phase 2 trial in 2022, and FDA Fast Track designation for 186RNL in treating leptomeningeal metastases.

Plus Therapeutics (PSTV) announced a partnership with Medidata to evaluate the Synthetic Control Arm (SCA) in a planned Phase 2 trial for Rhenium-186 NanoLiposome (186RNL) targeting recurrent glioblastoma. SCAs may improve patient enrollment and retention by using historical data to create control groups, thereby potentially lowering trial costs while maintaining scientific integrity. The FDA has recognized a Phase 3 trial design using synthetic controls, indicating a positive regulatory outlook for innovative trial methodologies.

Plus Therapeutics, Inc. (PSTV) will release its fourth quarter and full year 2021 financial results on February 24, 2022, after market close. Following the announcement, a conference call will be held at 5:00 p.m. ET to discuss the results and provide a corporate update. The call will be accessible via a live webcast on the company's investor relations page. Plus Therapeutics develops innovative radiotherapeutics for hard-to-treat cancers and is evaluating its lead product, Rhenium-186 NanoLiposome, in clinical trials.

Plus Therapeutics (Nasdaq: PSTV) announced that Marc H. Hedrick M.D., President and CEO, will present at the BIO CEO & Investor Conference on February 14, 2022, at 1:15 p.m. ET in New York City. The presentation will provide an overview of the company's innovative radiotherapeutics for rare cancers, focusing on their lead product, Rhenium-186 NanoLiposome, currently evaluated in clinical trials for treating recurrent glioblastoma. The live presentation can be accessed by registered participants via the conference website.

AUSTIN, Texas, Jan. 07, 2022 - Plus Therapeutics (Nasdaq: PSTV) announced that Marc H. Hedrick, M.D., will speak at two virtual conferences this January. The H.C. Wainwright BioConnect Conference will take place from January 10-13, with presentations available on demand starting January 10 at 7:00 a.m. ET. Additionally, the Biotech Showcase 2022 is scheduled for January 10-12 and 17-19, with on-demand access for presentations. Webcast replays and further information can be found on their website.

Plus Therapeutics has secured a worldwide exclusive license from UT Health San Antonio to develop innovative interventional radiotherapeutics for solid organ cancers. This deal enhances their proprietary Rhenium NanoLiposome technology, aiming to deliver targeted cancer therapies, specifically for liver cancer. The licensed technology includes biodegradable alginate microspheres to block blood flow to tumors while delivering high doses of cytotoxic compounds. An IND submission for liver cancer treatment is planned for 2022, tapping into a $1.3 billion market opportunity.

Plus Therapeutics (PSTV) has achieved key milestones in developing Rhenium-186 NanoLiposome (186RNL) radiotherapeutic. The company signed a master services agreement with IsoTherapeutics Group for cGMP grade Rhenium-186 isotope manufacturing, ensuring compliance with FDA standards for clinical trials. This agreement is expected to facilitate future clinical and commercial supply contracts. Furthermore, Plus Therapeutics has transferred analytical test methods to Piramal Pharma Solutions, paving the way for the cGMP drug product intermediate manufacturing, crucial for ongoing trials targeting difficult-to-treat cancers.